NCT01270399View on ClinicalTrials.gov

Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

UnknownOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
Trial Locations (1)

Unknown

RECRUITING

Meir Medical Center, Kfar Saba

Sponsors
All Listed Sponsors
lead

Meir Medical Center

OTHER

NCT01270399 - Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer | Biotech Hunter | Biotech Hunter